Hematologic Oncology | Specialty

Dr. Tallman on the State of the Science in AML Treatment

February 17th 2017

Martin S. Tallman, MD, hematologic oncologist, chief of Leukemia Service, Memorial Sloan Kettering Cancer Center, discusses the state of the science with regards to treatment of patients with acute myeloid leukemia (AML).

Dr. Neelapu on ZUMA-1 Trial Design of KTE-C19

February 17th 2017

Sattva S. Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the design of the ZUMA-1 trial of the chimeric antigen receptor (CAR) T-cell therapy KTE-C19 for patients with aggressive lymphomas.

Dr. Ansell on PD-1 Inhibitors in Hodgkin Lymphoma

February 17th 2017

Stephen M. Ansell, MD, PhD, of Mayo Clinic, discusses the use of PD-1 inhibitors for patients with Hodgkin lymphoma.

Dr. Straus on Ongoing Clinical Trials in Hodgkin Lymphoma

February 15th 2017

David J. Straus, MD, an internist and hematologic oncologist at Memorial Sloan Kettering Cancer Center, discusses ongoing clinical trials in the field of Hodgkin lymphoma.

Full FDA Approval Sought for Blinatumomab in Acute Lymphoblastic Leukemia

February 15th 2017

A supplemental biologics license application has been submitted to the FDA for the full regulatory approval of blinatumomab as a treatment for patients with Philadelphia chromosome-negative relapsed/refractory B-precursor acute lymphoblastic leukemia.

Dr. Chaudhary on Short-Term and Long-Term Future of CAR T-Cells

February 14th 2017

Preet M. Chaudhary, MD, PhD, chief of the Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, Department of Medicine, professor of Medicine, Ronald H. Bloom Family Chair in Lymphoma Research, and program director of the USC Norris Blood and Marrow Transplant Program, co-Leader of the Molecular Genetics Program, University of Southern California, discusses the short-term and long-term future of CAR T-cells.

Prevalence of Ph-like ALL in Adults Emphasizes Need for Targeted Clinical Trials

February 12th 2017

A recent study published in the Journal of Clinical Oncology has found that Philadelphia chromosome-like acute lymphoblastic leukemia (ALL) accounts for over 20% of all adult patients with ALL and is correlated with poor outcomes.

Dr. Reeder on Future Treatment Approaches in Aggressive Lymphomas

February 8th 2017

Craig B. Reeder, MD, assistant professor of Medicine, Mayo Clinic, discusses some future treatment approaches for patients with aggressive lymphomas, including diffuse large B-cell lymphoma.

Dr. Neelapu on Next Steps With KTE-C19 in Lymphoma

February 2nd 2017

Sattva S. Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the next steps with KTE-C19, an anti-CD19 chimeric antigen receptor T-cell therapy explored in the ZUMA-1 trial for patients with aggressive lymphomas.

Patients Say Benefits of Brentuximab Vedotin Offset Risk of Peripheral Neuropathy

January 31st 2017

Patients with lymphoma who are treated with brentuximab vedotin (BV) often experience peripheral neuropathy as an adverse event and potentially dose-limiting toxicity. A novel study has shown that, despite the prevalence of this toxicity, these patients report that the better outcomes yielded from treatment with BV outweigh the risk of neuropathy.

Expert Discusses Ibrutinib/Palbociclib Combo in Mantle Cell Lymphoma

January 30th 2017

Peter Martin, MD, discusses the efficacy of a combination regimen of ibrutinib and palbociclib in the treatment of patients with mantle cell lymphoma.

Combining and Sequencing BCR-ABL TKIs with Omacetaxine in CML

January 21st 2017

Toxicity for Omacetaxine in CML

January 21st 2017

Experience with Omacetaxine for TKI-Resistant TKI CML

January 21st 2017

Alternative Mechanism for Treatment of Resistant CML

January 21st 2017

Defining Suboptimal Response to BCR-ABL TKI Therapy in CML

January 21st 2017

FDA Approves Ibrutinib for Marginal Zone Lymphoma

January 19th 2017

The FDA has granted an accelerated approval to ibrutinib as a treatment for patients who require systemic therapy with marginal zone lymphoma following at least one prior anti-CD20-based therapy, based on findings from a single-arm phase II study.

Hodgkin Lymphoma Field Evolving With Immunotherapy, Adjustments to Standard Approaches

January 18th 2017

Since the FDA approval of nivolumab in May 2016, researchers continue to explore agent as well as its fellow PD-1 inhibitor, pembrolizumab, in various treatment settings for patients with Hodgkin lymphoma.

Frontline Ibrutinib Benefit Sustained in Pivotal CLL Trial Update

January 17th 2017

Danelle James, MD, discusses the updated RESONATE-2 data presented at the ASH Annual Meeting and the next steps with ibrutinib in CLL.

The Future of Treatment of B-Cell Lymphoma

January 13th 2017